GSK (London, UK / Philadelphia, PA) sponsors 304 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 128 active protocols (73 recruiting now), 130 completed protocols, and 116 all-time original FDA Drugs@FDA NDA and BLA approvals.